Azithromycin for the self-treatment of traveler's diarrhea

Clinical Infectious Diseases

Volumn 44, Issue 3, 2007, Pages 347-349

  DuPont, Herbert L ^a,b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b MC 1 164 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; LEVOFLOXACIN;

CAMPYLOBACTER; DOSAGE SCHEDULE COMPARISON; HUMAN; NAUSEA; NOTE; PRIORITY JOURNAL; SELF CARE; SINGLE DRUG DOSE; SOLDIER; THAILAND; TRAVEL; TRAVELLER DIARRHEA;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; COMMUNITY-ACQUIRED INFECTIONS; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; DYSENTERY; HUMANS; OFLOXACIN; SELF ADMINISTRATION; TRAVEL;

EID: 33846439402     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510594     Document Type: Note

References (30)

1. Tribble DR, Sanders JW, Pang LW, et al. E. Travelers' diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2006; 44:338-46 (in this issue).
2. Ericsson CD, DuPont HL, Mathewson JJ, Johnson PC, de la Cabada FJ, Bitsura JA. Test-of-cure stool cultures for traveler's diarrhea. J Clin Microbiol 1988; 26:1047-9.
3. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21:536-41.
4. Chongsuvivatwong V, Chariyalertsak S, McNeil E, et al. Traveller's diarrhoea among foreign visitors to Thailand: a report from the first four months [abstract A55]. In: Program and abstracts of the 11th Asian Conference on Diarrheal Diseases and Nutrition (Bangkok). Asian Conference on Diarrheal Diseases and Nutrition, 2006.
5. Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45:212-6.
6. Forestier C, Darfeuille-Michaud A, Joly B. Effects of antibiotics on adhesion of enterotoxigenic Escherichia coli strains. Eur J Clin Microbiol 1984; 3:427-32.
7. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821-7.
8. Hill DR. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. Am J Trop Med Hyg 2000; 62:585-9.
9. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001; 32:1706-9.
10. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002; 185: 497-502.
11. Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med 1991; 114:731-4.
12. Black RE. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 1990; 12:S73-9.
13. Taylor DN, Houston R, Shlim DR, Bhaibulaya M, Ungar BL, Echeverria P. Etiology of diarrhea among travelers and foreign residents in Nepal. JAMA 1988; 260:1245-8.
14. Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341-5.
15. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982-2001. Emerg Infect Dis 2002; 8:1501-3.
16. Saenz Y, Zarazaga M, Lantero M, Gastanares MJ, Baquero F, Torres C. Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998. Antimicrob Agents Chemother 2000; 44:267-71.
17. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33:1807-15.
18. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 2006; 74: 1060-6.
19. Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003; 37:1165-71.
20. Inagaki Y, Horiuchi S, Une T, Nakaya R. In-vitro activity of DR-3355, an optically active isomer of ofloxacin, against bacterial pathogens associated with travellers' diarrhoea. J Antimicrob Chemother 1989; 24:547-9.
21. Krausse R, Ullmann U. In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Antimicrob Agents Chemother 2003; 47: 2946-50.
22. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997; 126:697-703.
23. Luke DR, Foulds G. Disposition of oral azithromycin in humans. Clin Pharmacol Ther 1997; 61:641-8.
24. Rakita RM, Jacques-Palaz K, Murray BE. Intracellular activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1994; 38:1915-21.
25. Jiang ZD, Okhuysen PC, Guo DC, et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003; 188:506-11.
26. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805-12.
27. Gorbach SL. How to hit the runs for fifty million travelers at risk. Ann Intern Med 2005; 142:861-2.
28. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006; 42:1283-8.
29. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol 2006; 101: 1894-9; quiz 1942.
30. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99:1774-8.